久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Key vaccine in high demand, but supplies short

By LIU ZHIHUA | China Daily | Updated: 2019-07-05 07:08
Share
Share - WeChat
A woman has a 9-valent vaccine shot in Zhengzhou, capital of Henan province. Each year, some 131,500 new cervical cancer cases are reported in China, and about 53,000 patients die from the disease. ZHANG TAO/FOR CHINA DAILY

Once people can acquire the vaccination on a regular basis, the balance between supply and demand will be gradually restored, he said.

According to a report released earlier this year by Horizon Insights, a consultancy in Shanghai, some 300 million Chinese are in the recommended age group for the 2-valent vaccine, 130 million for the 4-valent, and 90 million for the 9-valent. Every year, 8 million people fall into the recommended age group for each vaccine.

Last year, 300,000 people were vaccinated with the 2-valent type, 1.1 million with the 4-valent, and only 100,000 with the 9-valent, resulting in market values of 500 million yuan, 2.7 billion yuan and 400 million yuan, the report said.

About 833,300 doses of the 2-valent vaccine, 3.41 million of the 4-valent and 1.22 million of the 9-valent were released on the market last year, according to the report.

It estimated that the market value for the 2-, 4-and 9-valent vaccines would reach 1 billion yuan, 7.2 billion yuan and 10 billion in times of peak demand.

There will continue to be a shortage of all three types until next year, as the huge demand that exists now cannot be met in a short period, the report said.

Zhao Heng, founder of consulting company Latitude Health, said the shortage could be resolved through increased production and distribution, but as the three types of vaccine are not on the national compulsory vaccination program, it is difficult for the authorities to order pharmaceutical companies to increase supplies.

However, more than a dozen Chinese pharmaceutical companies are developing HPV vaccines ranging from 2-valent to 14-valent, and some have started phase-3 clinical trials while others have only just received approval for such trials, according to the Horizon Insights report.

|<< Previous 1 2 3 4   
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 中文字幕 亚洲精品 | 99热在线观看 | 国产精品一国产精品免费 | 一级特黄性色生活片一区二区 | 国产精品久久久久久久久久一区 | 91久久亚洲精品国产一区二区 | 午夜不卡视频 | 一级做a爱过程免费视 | 久久99亚洲精品久久久久 | 欧美性猛交xxxxbbb | 三级理论手机在线观看视频 | 久久久毛片 | 黄网站色成年小说系列 | 亚洲日韩中文字幕在线播放 | 国内精品2020情侣视频 | 亚洲精品美女视频 | 久草网站在线 | 亚洲成人影院在线 | 国产高清免费在线 | 亚洲一区二区三区欧美 | 久久久久久久91精品免费观看 | 91成人软件 | 亚洲区一区| 欧美一区二区三区四区在线观看 | 亚洲网站在线播放 | 亚洲精品国产一区二区三区四区 | 免费一区二区三区久久 | 欧美一级特黄做 | 福利社在线视频 | 成人合成mv福利视频网站 | 久久久久国产精品免费网站 | 99超级碰碰成人香蕉网 | 午夜在线观看视频免费 成人 | 欧美成人一级视频 | 成人亚洲欧美日韩中文字幕 | 国产精彩视频在线观看 | 欧美日韩一区二区视频免费看 | 日本精品网 | 狠狠色狠狠色综合久久第一次 | 免费看岛国视频在线观看 | 无遮挡一级毛片私人影院 |